Current Edition

Regional News

Biogen piles on more long-term Aduhelm data, linking biomarker to Alzheimer’s clinical benefit

Despite a disastrous commercial rollout, Biogen is still producing longer-term data for beleaguered Alzheimer’s disease therapy Aduhelm. In patients who’ve been t...
Continue Reading →
Regional News

CMS’ Biogen decision could spell problems for Lilly, Roche Alzheimer’s drugs, half of surveyed neurologists say

Neurologists in the U.S. are agreeing with a new draft decision from the Centers for Medicare & Medicaid Services (CMS) that restricts reimbursement of Biogen’s c...
Continue Reading →
Regional News

Biogen’s Aduhelm records one patient death. Is the controversial Alzheimer’s drug to blame?

Doctors already have reservations about Biogen’s controversial Alzheimer’s disease drug, Aduhelm. Now a reported death will likely trigger more doubts around its use....
Continue Reading →
Regional News

Oncopeptides’ shares crash as it pulls Pepaxto from the market, plans to shut down commercial units

Because its drug for relapsed or refractory multiple myeloma may increase the risk of death, Swedish biotech Oncopeptides has sidelined the treatment in the U.S., a m...
Continue Reading →
Regional News

‘I don’t like it:’ Biogen’s latest Alzheimer’s ad rouses fresh Aduhelm concerns—and some defense

Maybe you occasionally forget appointments or social events or lose your train of thought in a conversation. Maybe you’re feeling depressed or overwhelmed when making...
Continue Reading →
Europe

AstraZeneca and Lilly’s Alzheimer’s drug fails trial

The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase 3 trial results. AstraZeneca and Eli Lilly’s lanabecesta...
Continue Reading →
news

First Ever Effective Intervention Against Dementia Shown in Large Study

Researchers just published the first randomized controlled trial ever to show an intervention effective at lowering the risk of dementia.  A computerized brain exerci...
Continue Reading →
Uncategorized

Amgen and Novartis Expand Alzheimer’s Collaboration with New Trial

Amgen and Novartis said today they will expand their two-year-old collaboration with the Banner Alzheimer’s Institute by launching a new Phase II/III trial designed t...
Continue Reading →